D-1000-2020 Class III Terminated
FDA drug recall D-1000-2020 was initiated by The Harvard Drug Group on Feb 27, 2020 and is designated Class III. Reason for recall: Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets. The recall status is terminated (terminated Sep 24, 2022). Affected quantity: 1 carton.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 18, 2020
- Initiation Date
- Feb 27, 2020
- Termination Date
- Sep 24, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1 carton
Product description
Quetiapine Fumarate Extended-Release Tablets, 150 mg, 100 tablets per unit dose carton, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.) 454775 India; Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA. NDC: 0904-6802-61
Reason for recall
Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.
Distribution pattern
Nationwide
Code information
Lot, expiry: Lot N00036, exp 05/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1000-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026